Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895 | 0.89 | GLA (0.37) | TYMP | |
| SCHEMBL2762904 | 0.87 | ALDH1A1 (0.35) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL14169365 | 0.87 | ALDH1A1 (0.38) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL3027900 | 0.82 | GAA (0.38) | — | |
| SCHEMBL3735333 | 0.81 | PARP1 (0.43) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL17949542 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL14003653 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL8438737 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL1257638 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MAPK1PARP1GPR84GSK3B | |
| SCHEMBL2454194 | 0.76 | PARP1 (0.42) | ALDH1A1MAPK1PARP1GPR84GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117276497-A | Asphalt-based coated resin-based hard carbon composite material and preparation method and application thereof | 常州烯源谷新材料科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-116735742-A | High performance liquid chromatography detection method for imidazole aldehyde and related substances thereof | 云南云天化股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-114605393-B | Method for preparing losartan by micro-channel continuous flow | 浙江工业大学 | 2023-06-27 | — | — | CN | claimed |
| US-11668708-B2 | Method for reducing measurement error in latex agglutination immunoassay | SEKISUI MEDICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | claimed |
| CN-114605393-A | Method for preparing losartan by micro-channel continuous flow | 浙江工业大学 | 2022-06-10 | — | — | CN | claimed |
| CN-112225702-A | Preparation method of 2-n-butyl-4-chloro-5-formylimidazole | 浙江花蝶染料化工有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-111592495-A | Preparation method of 2-n-butyl-4-chloro-5-formylimidazole | 上海启讯医药科技有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-111087388-A | Hydrazone group bridged naphthalimide imidazole compound and preparation method and application thereof | 西南大学 | 2020-05-01 | — | — | CN | claimed |
| CN-106995411-A | A kind of preparation method of the formyl imidazoles of 2 normal-butyl, 4 chlorine 5 | 滨海三甬药业化学有限公司 | 2017-08-01 | — | — | CN | claimed |
| CN-101838242-B | Method for synthesizing 2-normal-butyl-4-chloro-5-formylimidazole | UNIV ZHEJIANG TECHNOLOGY | 2015-07-15 | — | — | CN | claimed |
| EP-1871745-A2 | PREPARATION OF 2-SUBSTITUTED 4-CHLORO-5-FORMYLIMIDAZOLES BY VILSMEIER REACTION OF THE CONDENSATION PRODUCT OF GLYCINE AND AN IMIDO ESTER WITH A FORMAMIDE IN THE PRESENCE OF A TRIFLATE (TRIFLUORMETHANESULPHONATE) CATALYST | Disham Pharmaceuticals and Chemicals Ltd. (IN) | 2008-01-02 | — | — | EP | claimed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | claimed |
| WO-2007119246-A2 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF LOSARTAN POTASSIUM | UNICHEM LABORATORIES LIMITED (IN) | 2007-10-25 | — | — | WO | claimed |
| WO-2007020654-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LOSARTAN | SUVEN LIFE SCIENCES (IN) | 2007-02-22 | — | — | WO | claimed |
| WO-2006110037-A2 | PREPARATION OF 2-SUBSTITUTED 4-CHL0R0-5-F0RMYLIMIDAZ0LES BY VILSMEIER REACTION OF THE CONDENSATION PRODUCT OF GLYCINE AND AN IMIDO ESTER WITH A FORMAMIDE IN THE PRESENCE OF A TRIFLATE (TRIFLUORMETHANΞSULPHONATE) CATALYST | DISHMAN PHARMACEUTICALS AND CHEMICALS LTD. (IN) | 2006-10-19 | — | — | WO | claimed |
| US-7041832-B2 | Processes for preparing losartan and losartan potassium | TAVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-09 | — | — | US | claimed |
| WO-2006038223-A1 | A PROCESS FOR PREPARATION OF 2-N-BUTYL -4-CHLORO - 1 - {[2`- (2-TRIPHENYLMETHYL - 2H - TETRAZOLE - 5- YL) - 1, 1’ - BIPHENYL-4-YL] METHYL}-LH- IMIDAZOIE-5-METHANOL (INTERMEDIATE OF LOSARTAN) | MATRIX LABORATORIES LTD (IN) | 2006-04-13 | — | — | WO | claimed |
| EP-1474417-B1 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMA (IL) | 2006-03-22 | — | — | EP | claimed |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-02-19 | — | — | US | claimed |
| CN-1369492-A | Non-peptide angiotonin II receptor antagon Jw sartan compounds and its synthesizing process and application | WANG JIANWU (CN) | 2002-09-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | ALDH1A1 802/4885MAPK1 1106/4885PARP1 3577/4885 |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | REN, ACE, AGT | ALDH1A1 248/4885MAPK1 856/4885PARP1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.